162 related articles for article (PubMed ID: 3108458)
21. Steroid Profiling in Male Wobbler Mouse, a Model of Amyotrophic Lateral Sclerosis.
Gonzalez Deniselle MC; Liere P; Pianos A; Meyer M; Aprahamian F; Cambourg A; Di Giorgio NP; Schumacher M; De Nicola AF; Guennoun R
Endocrinology; 2016 Nov; 157(11):4446-4460. PubMed ID: 27571131
[TBL] [Abstract][Full Text] [Related]
22. Neuroprotective effect of ultra-high dose methylcobalamin in wobbler mouse model of amyotrophic lateral sclerosis.
Ikeda K; Iwasaki Y; Kaji R
J Neurol Sci; 2015 Jul; 354(1-2):70-4. PubMed ID: 25982504
[TBL] [Abstract][Full Text] [Related]
23. Aberrant deltaPKC activation in the spinal cord of Wobbler mouse: a model of motor neuron disease.
Dave KR; Raval AP; Purroy J; Kirkinezos IG; Moraes CT; Bradley WG; Pérez-Pinzón MA
Neurobiol Dis; 2005 Feb; 18(1):126-33. PubMed ID: 15649703
[TBL] [Abstract][Full Text] [Related]
24. Increase in fiber density for immunoreactive serotonin, substance P, enkephalin and thyrotropin-releasing hormone occurs during the early presymptomatic period of motoneuron disease in Wobbler mouse spinal cord ventral horn.
Bose P; Vacca-Galloway LL
Neurosci Lett; 1999 Feb; 260(3):196-200. PubMed ID: 10076901
[TBL] [Abstract][Full Text] [Related]
25. A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis.
Caroscio JT; Cohen JA; Zawodniak J; Takai V; Shapiro A; Blaustein S; Mulvihill MN; Loucas SP; Gudesblatt M; Rube D
Neurology; 1986 Feb; 36(2):141-5. PubMed ID: 3080693
[TBL] [Abstract][Full Text] [Related]
26. Neuron volume in the ventral horn in Wobbler mouse motoneuron disease: a light microscope stereological study.
Dockery P; Tang Y; Morais M; Vacca-Galloway LL
J Anat; 1997 Jul; 191 ( Pt 1)(Pt 1):89-98. PubMed ID: 9279662
[TBL] [Abstract][Full Text] [Related]
27. Neuronal nitric oxide synthase inhibitor, 7-nitroindazole, delays motor dysfunction and spinal motoneuron degeneration in the wobbler mouse.
Ikeda K; Iwasaki Y; Kinoshita M
J Neurol Sci; 1998 Sep; 160(1):9-15. PubMed ID: 9804111
[TBL] [Abstract][Full Text] [Related]
28. Progesterone neuroprotection in the Wobbler mouse, a genetic model of spinal cord motor neuron disease.
Gonzalez Deniselle MC; López-Costa JJ; Saavedra JP; Pietranera L; Gonzalez SL; Garay L; Guennoun R; Schumacher M; De Nicola AF
Neurobiol Dis; 2002 Dec; 11(3):457-68. PubMed ID: 12586554
[TBL] [Abstract][Full Text] [Related]
29. The 21-aminosteroid U-74389F attenuates hyperexpression of GAP-43 and NADPH-diaphorase in the spinal cord of wobbler mouse, a model for amyotrophic lateral sclerosis.
González Deniselle MC; González SL; Lima AE; Wilkin G; De Nicola AF
Neurochem Res; 1999 Jan; 24(1):1-8. PubMed ID: 9973230
[TBL] [Abstract][Full Text] [Related]
30. Decreased immunoreactive (IR) calcitonin gene-related peptide correlates with sprouting of IR-peptidergic and serotonergic neuronal processes in spinal cord and brain nuclei from the Wobbler mouse during motoneuron disease.
Zhang YQ; Vacca-Galloway LL
Brain Res; 1992 Jul; 587(1):169-77. PubMed ID: 1525646
[TBL] [Abstract][Full Text] [Related]
31. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.
Peviani M; Salvaneschi E; Bontempi L; Petese A; Manzo A; Rossi D; Salmona M; Collina S; Bigini P; Curti D
Neurobiol Dis; 2014 Feb; 62():218-32. PubMed ID: 24141020
[TBL] [Abstract][Full Text] [Related]
32. Decreased spinal cord cGMP in murine (wobbler) spontaneous lower motor neuron degeneration.
Brooks BR; Lust WD; Andrews JM; Engel WK
Arch Neurol; 1978 Sep; 35(9):590-1. PubMed ID: 210748
[TBL] [Abstract][Full Text] [Related]
33. Changes in receptor levels for thyrotropin releasing hormone, serotonin, and substance P in cervical spinal cord of Wobbler mouse: a quantitative autoradiography study during early and late stages of the motoneuron disease.
Deng YP; Li XS; Zhang SH; Vacca-Galloway LL
Brain Res; 1996 Jun; 725(1):49-60. PubMed ID: 8828585
[TBL] [Abstract][Full Text] [Related]
34. Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog.
Ohuchi K; Funato M; Kato Z; Seki J; Kawase C; Tamai Y; Ono Y; Nagahara Y; Noda Y; Kameyama T; Ando S; Tsuruma K; Shimazawa M; Hara H; Kaneko H
Stem Cells Transl Med; 2016 Feb; 5(2):152-63. PubMed ID: 26683872
[TBL] [Abstract][Full Text] [Related]
35. Treatment of amyotrophic lateral sclerosis with thyrotropin-releasing hormone (TRH).
Yamane K; Osawa M; Kobayashi I; Maruyama S
Jpn J Psychiatry Neurol; 1986 Jun; 40(2):179-87. PubMed ID: 3097367
[TBL] [Abstract][Full Text] [Related]
36. Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials.
Mitsumoto H; Salgado ED; Negroski D; Hanson MR; Salanga VD; Wilber JF; Wilbourn AJ; Breuer AC; Leatherman J
Neurology; 1986 Feb; 36(2):152-9. PubMed ID: 3080695
[TBL] [Abstract][Full Text] [Related]
37. Reduction of lower motor neuron degeneration in wobbler mice by N-acetyl-L-cysteine.
Henderson JT; Javaheri M; Kopko S; Roder JC
J Neurosci; 1996 Dec; 16(23):7574-82. PubMed ID: 8922414
[TBL] [Abstract][Full Text] [Related]
38. The distribution of histidyl-proline diketopiperazine [cyclo(His-Pro)] in discrete rat hypothalamic nuclei.
Yamada M; Wilber JF
Neuropeptides; 1989; 13(4):221-3. PubMed ID: 2501708
[TBL] [Abstract][Full Text] [Related]
39. The distribution of thyrotropin-releasing hormone (TRH) in the rhesus monkey spinal cord.
Lechan RM; Snapper SB; Jacobson S; Jackson IM
Peptides; 1984; 5 Suppl 1():185-94. PubMed ID: 6435101
[TBL] [Abstract][Full Text] [Related]
40. The serotoninergic bulbospinal system and brainstem-spinal cord content of serotonin-, TRH-, and substance P-like immunoreactivity in the aged rat with special reference to the spinal cord motor nucleus.
Johnson H; Ulfhake B; Dagerlind A; Bennett GW; Fone KC; Hökfelt T
Synapse; 1993 Sep; 15(1):63-89. PubMed ID: 7508641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
